Clinical Trials Browser

Nasopharyngeal Carcinoma

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Phase 3 Recruiting

266 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Phase 3 Recruiting

593 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07327216 2026-03-04

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Phase 3 Recruiting

180 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06976190 2026-01-20

Magic-C002

Phase 3 Recruiting

446 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Phase 3 Recruiting

300 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Phase 3 Recruiting

456 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Phase 3 Recruiting

346 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07303023 2025-12-24

INCIPT-NPC

Phase 3 Recruiting

462 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07188584 2025-12-09

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

Phase 3 Recruiting

166 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07201337 2025-11-17

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

Phase 3 Recruiting

550 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06235203 2025-06-03

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Phase 3 Recruiting

154 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07000643 2025-06-03

Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma

Phase 3 Recruiting

386 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06752239 2025-04-10

PROTECT-NPC

Phase 3 Recruiting

474 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Radiation Injuries, Thyroid Diseases

NCT06712888 2025-03-18

Navigation

Phase 3 Recruiting

466 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06629597 2025-02-10

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Recruiting

400 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03907826 2025-01-28

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Phase 3 Recruiting

212 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05780372 2025-01-28

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

Phase 3 Recruiting

474 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06675214 2024-11-05

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

Phase 3 Recruiting

586 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05979961 2024-08-06

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

454 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06516133 2024-07-23

OART

Phase 3 Recruiting

494 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06383780 2024-07-16

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Phase 3 Recruiting

90 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06438627 2024-07-16

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

Phase 3 Recruiting

164 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06277050 2024-04-30

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

264 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06092957 2023-12-15

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

Phase 3 Recruiting

504 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

Phase 3 Recruiting

228 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03919552 2023-06-18

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 3 Recruiting

482 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05877872 2023-05-26

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

424 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05854849 2023-05-11

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Phase 3 Recruiting

244 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT05527470 2023-05-03

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 3 Recruiting

440 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05772208 2023-03-16

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Phase 3 Recruiting

459 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05674305 2023-01-10

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Phase 3 Recruiting

366 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05145660 2022-09-27

Optimization of Cervical Nodal CTV for Early and Medium Stage NPC

Phase 3 Recruiting

414 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05340491 2022-08-31

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Phase 3 Recruiting

212 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04898374 2022-08-17

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Phase 3 Recruiting

120 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04437329 2022-05-10

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

Phase 3 Recruiting

352 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

556 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04376866 2021-07-20

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

204 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

218 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT04448522 2020-09-28

Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma

Phase 3 Recruiting

508 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04453813 2020-09-28

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

226 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04136886 2019-10-23

IMRT

Phase 3 Recruiting

346 enrolled

Head & Neck

Nasopharyngeal Carcinoma

Clinical Trials

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Magic-C002

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

INCIPT-NPC

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma

PROTECT-NPC

Navigation

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

OART

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

GNT Induction Treatment in Locally Advanced NPC

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Optimization of Cervical Nodal CTV for Early and Medium Stage NPC

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

IMRT